Ancestry, 23andMe and others say they will follow these rules when giving DNA data to businesses or police
By Tony Romm and Drew Harwell,
Washington Post
| 07. 31. 2018
Ancestry, 23andMe and other popular companies that offer genetic testing pledged on Tuesday to be upfront when they share users’ DNA data with researchers, hand it over to police or transfer it to other companies, a move aimed at addressing consumers' mounting privacy concerns.
Under the new guidelines, the companies said they would obtain consumers' “separate express consent” before turning over their individual genetic information to businesses and other third parties, including insurers. They also said they would disclose the number of law-enforcement requests they receive each year.
The new commitments come roughly three months after local investigators used a DNA-comparison service to track down a man police believed to be the Golden State Killer, who allegedly raped and killed dozens of women in California in the 1970s and 1980s. Investigators identified the suspect using a decades-old DNA sample obtained from the crime scene, which they uploaded to GEDmatch, a crowdsourced database of roughly a million distinct DNA sets shared by volunteers.
Investigators said they did not need a court order before using GEDmatch, sparking fresh fears that users’...
Related Articles
By Emily Mullin, Wired | 04.23.2026
A STARTUP OUT of Utah, Paterna Biosciences, says it has successfully grown functional human sperm in a lab and used the sperm to make visibly healthy-looking embryos. The technique could eventually help men with certain types of infertility have biological children...
By Julianna LeMieux, Genetic Engineering & Biotechnology News | 04.14.2026
Twenty years ago, Sven Bocklandt, PhD, sought to create a hypoallergenic cat. He had the genetic engineering chops to do it, but the embryology was beyond his capabilities. At a small animal genetic engineering conference, known as TARC (Transgenic Animal...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...